Table 3.
Characteristics by baseline Orthodema score.
| Baseline Orthodema Score 1 or 2 | Baseline Orthodema Score 3 or 4 | P-Value for Any Difference |
|
|---|---|---|---|
| Age | |||
| N | 163 | 300 | 0.54 |
| Median (25th, 75th) | 69 ( 59, 78) | 68 ( 57, 78) | |
| Mean +/− SD | 68 +/− 13 | 67+/− 14 | |
| Sex, N (%) | |||
| Male | 118 (72) | 222 (74) | 0.71 |
| Female | 45 (28) | 78 (26) | |
| SBP | |||
| N | 163 | 298 | 0.44 |
| Median (25th, 75th) | 113 (104,125) | 116 (103,130) | |
| Mean +/− SD | 117+/− 19 | 119+/− 19 | |
| HR | |||
| N | 162 | 300 | 0.55 |
| Median (25th, 75th) | 75 ( 68, 83) | 76 ( 68, 86) | |
| Mean +/− SD | 77+/− 14 | 78+/− 17 | |
| ACE-inhibitor at baseline, N (%) | |||
| Yes | 68 (42) | 112 (37) | 0.36 |
| No | 95 (58) | 188 (63) | |
| ARB at baseline, N (%) | |||
| Yes | 38 (23) | 52 (17) | 0.12 |
| No | 125 (77) | 248 (83) | |
| ACE/ARB at baseline, N (%) | |||
| Yes | 103 (63) | 157 (52) | 0.024 |
| No | 60 (37) | 143 (48) | |
| Beta blocker at baseline, N (%) | |||
| Yes | 137 (84) | 240 (80) | 0.28 |
| No | 26 (16) | 60 (20) | |
| Aldosterone antagonist at baseline, N (%) | |||
| Yes | 41 (25) | 80 (27) | 0.73 |
| No | 122 (75) | 220 (73) | |
| Calcium channel blocker at baseline, N (%) | |||
| Yes | 27 (17) | 52 (17) | 0.83 |
| No | 136 (83) | 248 (83) | |
| BMI | |||
| N | 155 | 285 | 0.023 |
| Median (25th, 75th) | 31 (26, 37) | 33 (28, 40) | |
| Mean +/− SD | 32+/− 8 | 35+/− 10 | |
| PVD, N (%) | |||
| Yes | 28 (17) | 51 (17) | 0.96 |
| No | 135 (83) | 249 (83) | |
| Diabetes, N (%) | |||
| Yes | 85 (52) | 176 (59) | 0.18 |
| No | 78 (48) | 124 (41) | |
| Gout, N (%) | |||
| Yes | 37 (23) | 66 (22) | 0.86 |
| No | 126 (77) | 234 (78) | |
| Smoking history, N (%) | |||
| Current | 21 (13) | 34 (11) | 1.0 |
| Quit < 6 months | 8 (5) | 10 (3) | |
| Quit >= 6 months | 77 (47) | 158 (53) | |
| Never | 57 (35) | 98 (33) | |
| LVEF | |||
| N | 162 | 293 | 0.84 |
| Median (25th, 75th) | 31 ( 20, 55) | 30 ( 20, 55) | |
| Mean +/− SD | 36+/− 18 | 36+/− 18 | |
| HF Etiology | |||
| Ischemic | 102 (63) | 164 (55) | 1.0 |
| Non-Ischemic | 61 (37) | 136 (45) | |
| Number CV hosp past 12 mo | |||
| N | 161 | 295 | 0.26 |
| Median (25th, 75th) | 1 (1, 3) | 2 (1,3) | |
| Mean +/− SD | 2+/− 2 | 2+/− 2 | |
| Number HF hosp past 12 mo | 161 | 295 | 0.15 |
| N | 161 | 295 | 0.15 |
| Median (25th, 75th) | 1.0 ( 0.0, 2.0) | 1.0 ( 1.0, 2.0) | |
| Mean +/− SD | 1.5+/− 1.5 | 1.7+/− 1.7 | |
| BUN | 163 | 300 | 0.38 |
| N | 163 | 300 | 0.38 |
| Median (25th, 75th) | 38 (25, 56) | 40 (25, 58) | |
| Mean +/− SD | 42+/− 23 | 44.4+/− 24.6 | |
| Local Lab Creatinine | |||
| N | 163 | 298 | 0.017 |
| Median (25th, 75th) | 1.7 (1.2, 2.1) | 1.8 (1.3, 2.3) | |
| Mean +/− SD | 1.69+/− 0.59 | 1.85+/− 0.63 | |
| GFR | |||
| N | 163 | 298 | 0.085 |
| Median (25th, 75th) | 42 (32, 59) | 40 (29, 57) | |
| Mean +/− SD | 49.5+/− 25.6 | 45.2+/− 21.1 | |
| Hemoglobin | |||
| N | 160 | 296 | 0.02 |
| Median (25th, 75th) | 11.7 ( 10.3, 12.8) | 11.1 (9.8, 12.5) | |
| Mean +/− SD | 11.6 +/− 1.8 | 11.2 +/− 1.9 | |
| Pre-Hospital/Qualifying Furosemide Dose | |||
| N | 163 | 300 | 0.83 |
| Median (25th, 75th) | 120 (80, 160) | 120 (80, 160) | |
| Mean +/− SD | 133+/− 89 | 139+/− 101 |
SBP= systolic blood pressure; HR = heart rate; ACE inhibitor = angiotensin converting enzyme inhibitor; ARB= angiotensin receptor blocker; BMI = body mass index; PVD = peripheral vascular disease; LVEF = left ventricular ejection fraction; HF = heart failure; CV = cardiovascular; Hosp = hospitalizations; BUN = blood urea nitrogen; GFR = glomerular filtration rate